ABOS

MKT CAP:$158M

Acumen Pharmaceuticals, Inc.

Market Cap

$158M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$2.67+$0.65 (+32.18%)

Apr 23, 2026

Company Details

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanize...

CEO

James Doherty

IPO Date

Jul 1, 2021

Website

acumenpharm.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$121M

EPS (Diluted)

-$2.02

Free Cash Flow

-$116M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

FY 2025

Mar 26, 2026

$0EPS -$2.00

Q4 2025

Mar 26, 2026

$0EPS -$0.42

Q3 2025

Nov 12, 2025

$0EPS -$0.44

Q2 2025

Aug 12, 2025

$0EPS -$0.68

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$6M	-$9M
Q2 22	$0	-$7M	-$10M
Q3 22	$0	-$8M	-$11M
Q4 22	$0	-$11M	-$14M
Q1 23	$0	-$9M	-$13M
Q2 23	$0	-$9M	-$13M
Q3 23	$0	-$473.0K	-$16M
Q4 23	$0	-$39.0K	-$18M
Q1 24	$0	$0	-$18M
Q2 24	$0	$0	-$24M
Q3 24	$0	$0	-$32M
Q4 24	$0	-$44.0K	-$40M
Q1 25	$0	$0	-$30M
Q2 25	$0	$0	-$42M
Q3 25	$0	$0	-$27M
Q4 25	$0	-$45.0K	-$25M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$8M	-$8M
Q2 22	-$6M	-$7M
Q3 22	-$9M	-$9M
Q4 22	-$11M	-$11M
Q1 23	-$10M	-$10M
Q2 23	-$12M	-$12M
Q3 23	-$13M	-$13M
Q4 23	-$8M	-$8M
Q1 24	-$18M	-$18M
Q2 24	-$17M	-$17M
Q3 24	-$25M	-$25M
Q4 24	-$27M	-$27M
Q1 25	-$34M	-$34M
Q2 25	-$32M	-$32M
Q3 25	-$30M	-$30M
Q4 25	-$19M	-$19M

Capital Expenditures

Quarter	CapEx
Q1 22	$9.0K
Q2 22	$36.0K
Q3 22	$81.0K
Q4 22	$35.0K
Q1 23	$0
Q2 23	$0
Q3 23	$7.0K
Q4 23	$14.0K
Q1 24	$11.0K
Q2 24	$5.0K
Q3 24	$0
Q4 24	$0
Q1 25	$79.0K
Q2 25	$9.0K
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+142.7%
Q2 22	—	+202.6%
Q3 22	—	+189.0%
Q4 22	—	+69.3%
Q1 23	—	+42.7%
Q2 23	—	+29.5%
Q3 23	—	+41.1%
Q4 23	—	+29.7%
Q1 24	—	+35.3%
Q2 24	—	+80.9%
Q3 24	—	+101.2%
Q4 24	—	+114.2%
Q1 25	—	+70.9%
Q2 25	—	+71.2%
Q3 25	—	-17.8%
Q4 25	—	-36.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$618.0K	—
Q2 22	$715.0K	—
Q3 22	$840.0K	—
Q4 22	$888.0K	—
Q1 23	$1M	—
Q2 23	$2M	—
Q3 23	$2M	—
Q4 23	$2M	—
Q1 24	$2M	—
Q2 24	$2M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$0	—
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$6M	$3M	—
Q2 22	$7M	$3M	—
Q3 22	$8M	$3M	—
Q4 22	$11M	$4M	—
Q1 23	$9M	$4M	—
Q2 23	$9M	$4M	—
Q3 23	$11M	$5M	—
Q4 23	$13M	—	$5M
Q1 24	$12M	$5M	—
Q2 24	$20M	$5M	—
Q3 24	$27M	$5M	—
Q4 24	$35M	$5M	—
Q1 25	$25M	$5M	—
Q2 25	$37M	$5M	—
Q3 25	$22M	—	$5M
Q4 25	$21M	$5M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$109M	$80M	$189M
Q2 22	$111M	$79M	$190M
Q3 22	$158M	$43M	$200M
Q4 22	$130M	$48M	$178M
Q1 23	$78M	$62M	$140M
Q2 23	$77M	$68M	$145M
Q3 23	$95M	$121M	$215M
Q4 23	$67M	$177M	$244M
Q1 24	$47M	$206M	$253M
Q2 24	$68M	$193M	$260M
Q3 24	$33M	$167M	$200M
Q4 24	$36M	$136M	$172M
Q1 25	$30M	$119M	$149M
Q2 25	$37M	$107M	$143M
Q3 25	$47M	$80M	$127M
Q4 25	$54M	$63M	$117M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	40M	+5.8%	+9.4%
Q2 22	40M	+0.1%	+4.8%
Q3 22	41M	+0.0%	+5.8%
Q4 22	41M	+0.9%	+6.8%
Q1 23	41M	+0.4%	+1.4%
Q2 23	41M	0.0%	+1.3%
Q3 23	54M	+32.2%	+33.9%
Q4 23	58M	+7.0%	+42.0%
Q1 24	60M	+3.1%	+45.8%
Q2 24	60M	+0.4%	+46.4%
Q3 24	60M	0.0%	+10.8%
Q4 24	60M	-0.1%	+3.4%
Q1 25	61M	+0.9%	+1.2%
Q2 25	61M	+0.1%	+0.8%
Q3 25	61M	0.0%	+0.8%
Q4 25	61M	-0.0%	+0.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	17
Q2 22	$0	17
Q3 22	$0	17
Q4 22	$0	40
Q1 23	$0	40
Q2 23	$0	40
Q3 23	$0	40
Q4 23	$0	52
Q1 24	$0	52
Q2 24	$0	52
Q3 24	$0	52
Q4 24	$0	61
Q1 25	$0	61
Q2 25	$0	61
Q3 25	$0	61
Q4 25	$0	61

Revenue / Employee